



Comment on “Elucidating the molecular mechanisms of perfluorodecanoic acid and perfluorooctane sulfonic acid on glioblastoma through network toxicology and bioinformatics”

Wenjun Jiang, MBBS^a, Qin Zheng, PhD^{b,*}, Jingyi Han, MBBS^{a,*}

To the Editor,

We read with great interest the recent study by Chen *et al*^[1] titled “Elucidating the molecular mechanisms of perfluorodecanoic acid and perfluorooctane sulfonic acid on glioblastoma through network toxicology and bioinformatics”. The authors successfully constructed a “PFASs–Targets–GBM” network and experimentally validated that perfluorodecanoic acid (PFDA) and perfluorooctane sulfonic acid (PFOS) exposure can enhance the proliferation and migration of glioblastoma (GBM) cells via the MMP2/MMP9 axis. We commend the authors for their innovative approach in bridging environmental toxicology with neuro-oncology, highlighting a potential, yet overlooked, environmental risk factor for GBM progression. However, to translate these *in vitro* findings into a valid clinical or epidemiological warning, two pivotal pharmacokinetic factors warrant further discussion.

Physiological relevance of exposure dosages

A critical challenge in toxicological studies is the “dose-response” discrepancy between laboratory models and environmental reality. The study demonstrated the oncogenic effects of PFDA/PFOS at specific experimental concentrations^[1]. However, human environmental exposure is typically chronic

and low-dose. The serum concentrations of PFASs in the general population are often in the nanomolar (nM) range, whereas *in vitro* assays often employ micromolar (μM) concentrations to elicit observable phenotypes. It is crucial to clarify whether the concentrations used in the validation experiments align with clinically relevant cumulative levels found in human brain tissue. If the oncogenic phenotype is only observable at supraphysiological doses, the actual risk to GBM patients from standard environmental exposure might be overestimated. We suggest that future validation should involve chronic low-dose exposure assays, which better mimic real-world scenarios.

The blood–brain barrier permeability factor

Unlike peripheral tumors, GBM resides behind the blood–brain barrier (BBB). For systemic pollutants like PFDA/PFOS to directly modulate MMP2/MMP9 expression in glioblastoma cells, they must effectively cross the neurovascular unit. While some perfluoroalkyl substances have been detected in brain tissue, their transport efficiency varies significantly by chain length and functional group. The current study’s mechanism relies on direct interaction between the chemicals and GBM cells^[1]. Without accounting for BBB permeability, the “network” links may remain theoretical. We recommend that future studies incorporate BBB *in vitro* models (e.g. transwell co-culture with endothelial cells) to verify that PFDA/PFOS can indeed reach the tumor site in sufficient quantities to trigger the observed molecular changes.

Conclusion

In summary, Chen *et al*^[1] provide a pioneering framework linking PFASs to GBM. Addressing the issues of dosage relevance and BBB penetration would significantly strengthen the causal link proposed in this study and guide future epidemiological investigations.

Ethical approval

Not applicable.

Consent

Not applicable.

^aDepartment of Clinical Laboratory, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China and ^bDepartment of Biochemistry and Molecular Biology, Liaoning Provincial Core Lab of Glycobiology and Glycoengineering, College of Basic Medical Sciences, Dalian Medical University, Dalian, Liaoning, China

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

*Corresponding authors. Address: Department of Clinical Laboratory, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China. Tel.: +86 0411-83635963-2232. E-mail: jingyi7236@163.com (J. Han); Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Dalian Medical University, Dalian, Liaoning 116044, China. Tel.: +86-18642866156. E-mail: zhengqin90@126.com (Q. Zheng).

Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

International Journal of Surgery (2026) 112:12992–12993

Received 30 January 2026; Accepted 18 February 2026

Published online 12 March 2026

<http://dx.doi.org/10.1097/JS9.0000000000005045>

Sources of funding

Not applicable.

Author contributions

Writing original draft: W.J.J.; writing – review and editing: Q.Z. and J.Y.H.

Conflicts of interest disclosure

The authors declare that they have no competing interests.

Research registration unique identifying number (UIN)

Not applicable.

Guarantor

Qin Zheng.

Provenance and peer review

Not commissioned.

Data availability statement

Not applicable.

Acknowledgements

Not applicable.

Reference

- [1] Chen T, Liang H, Huang Q, Sun X. Elucidating the molecular mechanisms of perfluorodecanoic acid and perfluorooctane sulfonic acid on glioblastoma through network toxicology and bioinformatics. *Int J Surg* 2026;112:4253–54.